Skip to main content
Clinical Trials/NL-OMON52323
NL-OMON52323CompletedPhase 4

A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual Antiplatelet Therapy (DAPT). - BIOFLOW-DAPT study

BIOTRONIK AG0 sites1 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
1

Study Overview

Brief Summary

Trial is onging in other countries

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • - An acceptable candidate for treatment with a Drug Eluting Stent (DES)
  • - Considered at high bleeding risk
  • - >= 18 years old

Exclusion Criteria

  • - previously experienced stent or scaffold thrombosis in any coronary vessel.
  • - Revascularization of any target vessel within 9 months prior to the index
  • procedure or previous PCI of any non-target vessel within 72 hours prior to or
  • during the index procedure.
  • - judged by physician as inappropriate for discontinuation from DAPT at 1 month
  • following index procedure, due to another condition requiring chronic DAPT.

Investigators

Similar Trials